PE20141974A1 - Compuestos de heterociclilo - Google Patents

Compuestos de heterociclilo

Info

Publication number
PE20141974A1
PE20141974A1 PE2014001400A PE2014001400A PE20141974A1 PE 20141974 A1 PE20141974 A1 PE 20141974A1 PE 2014001400 A PE2014001400 A PE 2014001400A PE 2014001400 A PE2014001400 A PE 2014001400A PE 20141974 A1 PE20141974 A1 PE 20141974A1
Authority
PE
Peru
Prior art keywords
cycloalkyl
alkyl
compounds
dimethylpyride
triona
Prior art date
Application number
PE2014001400A
Other languages
English (en)
Inventor
Bhavesh Dave
Rakesh Kumar Banerjee
Samiron Phukan
Abhijit Datta Khoje
Rajkumar Hangarge
Jitendra Sambhaji Jadhav
Venkata P Palle
Rajender Kumar Kamboj
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47997632&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20141974(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of PE20141974A1 publication Critical patent/PE20141974A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

SE REFIERE A COMPUESTOS HETEROCICLICOS DE FORMULA (I) DONDE R1 ES H, ALQUILO, CICLOALQUILO, ENTRE OTROS; R2 ES -SO2R7, -C(O)R8, ENTRE OTROS, EN DONDE R7 ES CICLOALQUILO O CICLOALQUENILO; R8 ES ALQUILO, ALQUENILO, ENTRE OTROS; R3 ES H, ALQUILO O CICLOALQUILO; R4 ES H, HALOGENO, ALQUILO O CICLOALQUILO; R5 ES ARILO OPCIONALMENTE SUSTITUIDO CON Ra Y Rb, EN DONDE Ra Y Rb SON CADA UNO H, HALOGENO O HALOALQUILO. SON COMPUESTOS PREFERIDOS: 1-(3-(CICLOPROPILSULFONIL)FENIL)-5-((2-FLUORO-4-YODOFENIL)AMINO)-6,8-DIMETILPIRIDO[4,3-d]PIRIMIDINA-2,4,7(1H,3H,6H)-TRIONA; 3-CICLOPROPIL-1-(2-FLUORO-4-YODOFENIL)-5-((3-(3-HIDROXIAZETIDIN-1-IL)FENIL)AMINO)-6,8-DIMETILPIRIDO[2,3-d]PIRIMIDINA-2,4,7(1H,3H,8H)-TRIONA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA QUINASA MEK SIENDO UTILES EN EL TRATAMIENTO DE CANCER, PSORIASIS, RESTENOSIS
PE2014001400A 2012-03-14 2013-03-11 Compuestos de heterociclilo PE20141974A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN288KO2012 2012-03-14

Publications (1)

Publication Number Publication Date
PE20141974A1 true PE20141974A1 (es) 2014-12-12

Family

ID=47997632

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2014001399A PE20141973A1 (es) 2012-03-14 2013-03-11 Compuestos de heterociclilo como inhibidores de mek
PE2014001400A PE20141974A1 (es) 2012-03-14 2013-03-11 Compuestos de heterociclilo

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2014001399A PE20141973A1 (es) 2012-03-14 2013-03-11 Compuestos de heterociclilo como inhibidores de mek

Country Status (36)

Country Link
US (5) US9428499B2 (es)
EP (2) EP2834237B1 (es)
JP (3) JP6431770B2 (es)
KR (4) KR102240101B1 (es)
CN (4) CN108383836B (es)
AP (2) AP3859A (es)
AU (4) AU2013234014B2 (es)
BR (1) BR112014022713B1 (es)
CA (2) CA2865167C (es)
CL (2) CL2014002412A1 (es)
CO (2) CO7170131A2 (es)
CR (2) CR20140463A (es)
CU (2) CU24335B1 (es)
DK (2) DK2834237T3 (es)
DO (2) DOP2014000204A (es)
EA (2) EA028232B1 (es)
ES (2) ES2684517T3 (es)
GE (2) GEP201706774B (es)
GT (2) GT201400195A (es)
HK (2) HK1202538A1 (es)
IL (2) IL234560A (es)
IN (2) IN2014MN01755A (es)
MA (2) MA37405A1 (es)
MX (3) MX366426B (es)
MY (2) MY174188A (es)
NI (2) NI201400107A (es)
NZ (2) NZ629432A (es)
PE (2) PE20141973A1 (es)
PH (2) PH12014502040B1 (es)
PL (1) PL2834237T3 (es)
SG (2) SG11201405006PA (es)
TN (2) TN2014000357A1 (es)
TR (1) TR201811976T4 (es)
UA (2) UA114906C2 (es)
WO (2) WO2013136254A1 (es)
ZA (1) ZA201406186B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
CN108383836B (zh) * 2012-03-14 2021-11-12 鲁宾有限公司 作为mek抑制剂的杂环基化合物
IL289834B1 (en) 2012-06-13 2024-03-01 Incyte Holdings Corp Conversion of tricyclic compounds as FGFR inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
SI2986610T1 (en) 2013-04-19 2018-04-30 Incyte Holdings Corporation Bicyclic heterocycles as inhibitors of FGFR
CN104936945B (zh) 2013-10-25 2017-11-03 上海恒瑞医药有限公司 吡啶酮类衍生物、其制备方法及其在医药上的应用
WO2016009306A1 (en) * 2014-07-15 2016-01-21 Lupin Limited Heterocyclyl compounds as mek inhibitors
WO2016035008A1 (en) * 2014-09-04 2016-03-10 Lupin Limited Pyridopyrimidine derivatives as mek inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
ES2751669T3 (es) 2015-02-20 2020-04-01 Incyte Corp Heterociclos bicíclicos como inhibidores FGFR
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
HUE062076T2 (hu) 2017-12-21 2023-09-28 Boehringer Ingelheim Int Benzilamino-szubsztituált piridopirimidinonok és származékai mint sos1
EP3788047A2 (en) 2018-05-04 2021-03-10 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
MX2020011639A (es) 2018-05-04 2021-02-15 Incyte Corp Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr).
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2020254451A1 (en) 2019-06-19 2020-12-24 Boehringer Ingelheim International Gmbh Anticancer combination therapy
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
BR112022001678A2 (pt) * 2019-07-30 2022-05-03 Edvince Ab Inibidor mek, uso de um inibidor mek, método de tratar ou reduzir o risco de desenvolver um acidente vascular cerebral em um sujeito, composição, e, kit de partes
EP3797899A1 (de) 2019-09-27 2021-03-31 Primetals Technologies Austria GmbH Vorrichtung und verfahren zum erkennen von einer bewegung eines körpers in einer industrieanlage
BR112022007163A2 (pt) 2019-10-14 2022-08-23 Incyte Corp Heterociclos bicíclicos como inibidores de fgfr
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
KR20220131900A (ko) 2019-12-04 2022-09-29 인사이트 코포레이션 Fgfr 억제제의 유도체
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
KR20230019462A (ko) 2020-06-02 2023-02-08 베링거 인겔하임 인터내셔날 게엠베하 암 치료용 고리형 2-아미노-3-시아노 티오펜 및 유도체
TWI825637B (zh) 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶－１，６（２ｈ，７ｈ）－二酮
EP4319757A1 (en) 2021-04-09 2024-02-14 Boehringer Ingelheim International GmbH Anticancer therapy
CA3215081A1 (en) * 2021-04-16 2022-10-20 Alfredo C. Castro Mek inhibitors and uses thereof
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2023099592A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2023099623A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
TW202337431A (zh) 2021-12-01 2023-10-01 德商百靈佳殷格翰國際股份有限公司 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
TW202337432A (zh) 2021-12-01 2023-10-01 德商百靈佳殷格翰國際股份有限公司 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
WO2023099620A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes
CN114573582B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 1,2,3,4-四氢吡啶并[2,3-d]嘧啶类化合物及其制备方法和应用
CN114605408B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-羟基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制法和应用
CN114573581B (zh) * 2022-03-30 2023-09-01 沈阳药科大学 5-取代氨基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
CN114456166B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-取代氨基-3-甲基吡啶并[2,3-d]嘧啶类化合物及其制备与应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
UA72612C2 (en) * 2000-07-06 2005-03-15 Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
US6825180B2 (en) * 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
GB0129099D0 (en) 2001-12-05 2002-01-23 Astrazeneca Ab Chemical compounds
KR20060111716A (ko) * 2002-01-22 2006-10-27 워너-램버트 캄파니 엘엘씨 2-(피리딘-2-일아미노)-피리도[2,3-ｄ]피리미딘-7-온
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
US7772234B2 (en) 2003-11-19 2010-08-10 Array Biopharma Inc. Bicyclic inhibitors of MEK and methods of use thereof
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
RS52670B (en) * 2004-06-11 2013-06-28 Japan Tobacco Inc. 5-AMINO-2,4,7-TRIOXO-3,4,7,8-TETRAHYDRO-2H-PIRIDO (2,3-D) PYRIMIDINE DERIVATIVES AND SIMILAR COMPOUNDS FOR CANCER TREATMENT
CA2761108A1 (en) 2009-04-21 2010-10-28 Novartis Ag Heterocyclic compounds as mek inhibitors
CN108383836B (zh) 2012-03-14 2021-11-12 鲁宾有限公司 作为mek抑制剂的杂环基化合物

Also Published As

Publication number Publication date
CA2865164C (en) 2021-06-08
CN104203947A (zh) 2014-12-10
CL2014002411A1 (es) 2015-04-06
IL234560A (en) 2017-06-29
BR112014022713A2 (es) 2017-06-20
IN2014MN01755A (es) 2015-07-03
CN108383836B (zh) 2021-11-12
MY175950A (en) 2020-07-16
TN2014000356A1 (en) 2015-12-21
CU24272B1 (es) 2017-08-08
ES2741896T3 (es) 2020-02-12
MA37400A1 (fr) 2016-05-31
MX355474B (es) 2018-04-16
AP3859A (en) 2016-10-31
NZ629432A (en) 2017-01-27
US9428499B2 (en) 2016-08-30
TR201811976T4 (tr) 2018-09-21
CR20140463A (es) 2014-11-28
CA2865164A1 (en) 2013-09-19
DK2834237T3 (en) 2018-08-27
PH12014502041A1 (en) 2014-11-24
KR20190073597A (ko) 2019-06-26
CU24335B1 (es) 2018-04-03
AP2014008008A0 (en) 2014-10-31
MX2014010928A (es) 2015-04-10
KR102240101B1 (ko) 2021-04-14
AU2018202568B2 (en) 2019-05-09
KR102241111B1 (ko) 2021-04-15
PH12014502041B1 (en) 2014-11-24
CO7160029A2 (es) 2015-01-15
EA201491672A1 (ru) 2014-12-30
IN2014MN01754A (es) 2015-07-03
HK1206020A1 (en) 2015-12-31
ZA201406186B (en) 2016-06-29
CR20140464A (es) 2014-11-28
CN108383836A (zh) 2018-08-10
DOP2014000204A (es) 2015-02-15
AU2013234014B2 (en) 2017-02-02
NZ629442A (en) 2016-12-23
CA2865167A1 (en) 2013-09-19
DOP2014000203A (es) 2015-02-15
CN107698585A (zh) 2018-02-16
DK2834236T3 (da) 2019-08-26
MY174188A (en) 2020-03-12
UA114906C2 (uk) 2017-08-28
EP2834237B1 (en) 2018-06-06
MA37400B1 (fr) 2019-11-29
US20170112840A1 (en) 2017-04-27
AU2013234009A1 (en) 2014-09-25
NI201400107A (es) 2014-11-26
US9573944B2 (en) 2017-02-21
IL234559A (en) 2017-06-29
US9555035B2 (en) 2017-01-31
EP2834236B1 (en) 2019-05-22
CA2865167C (en) 2019-08-06
CN104271577A (zh) 2015-01-07
CU20140109A7 (es) 2014-11-27
AU2013234014A1 (en) 2014-09-25
EA029768B1 (ru) 2018-05-31
MA37405A1 (fr) 2016-03-31
MX366426B (es) 2019-07-08
GEP201706774B (en) 2017-11-27
EA201491671A1 (ru) 2014-12-30
KR20190100472A (ko) 2019-08-28
MX2014010925A (es) 2015-04-10
US9827247B2 (en) 2017-11-28
PE20141973A1 (es) 2014-12-12
WO2013136254A1 (en) 2013-09-19
AP3834A (en) 2016-09-30
JP6630771B2 (ja) 2020-01-15
MX355526B (es) 2018-04-20
HK1202538A1 (en) 2015-10-02
TN2014000357A1 (en) 2015-12-21
PH12014502040A1 (en) 2014-11-24
GEP201706671B (en) 2017-05-25
KR20140138911A (ko) 2014-12-04
UA114907C2 (uk) 2017-08-28
EA028232B1 (ru) 2017-10-31
CL2014002412A1 (es) 2015-03-06
US20170101408A1 (en) 2017-04-13
WO2013136249A1 (en) 2013-09-19
SG11201405007QA (en) 2014-10-30
EP2834237A1 (en) 2015-02-11
US9969731B2 (en) 2018-05-15
US20150133424A1 (en) 2015-05-14
EP2834236A1 (en) 2015-02-11
PH12014502040B1 (en) 2014-11-24
NI201400108A (es) 2014-11-28
JP2015509975A (ja) 2015-04-02
ES2684517T3 (es) 2018-10-03
GT201400195A (es) 2017-11-09
AU2013234009B2 (en) 2016-10-27
PL2834237T3 (pl) 2018-11-30
JP6431770B2 (ja) 2018-11-28
AP2014008009A0 (en) 2014-10-31
JP2015514056A (ja) 2015-05-18
US20160331753A1 (en) 2016-11-17
AU2018202568A1 (en) 2018-05-10
GT201400196A (es) 2017-09-28
CU20140110A7 (es) 2014-11-27
AU2017200493B2 (en) 2018-03-29
JP6093384B2 (ja) 2017-03-08
US20150299186A1 (en) 2015-10-22
BR112014022713B1 (pt) 2021-09-08
CO7170131A2 (es) 2015-01-28
AU2017200493A1 (en) 2017-02-16
SG11201405006PA (en) 2014-10-30
JP2018115215A (ja) 2018-07-26
KR20140138910A (ko) 2014-12-04

Similar Documents

Publication Publication Date Title
PE20141974A1 (es) Compuestos de heterociclilo
PE20161443A1 (es) Compuestos
PE20141404A1 (es) Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas
PE20130306A1 (es) Morfolinopirimidinas y su uso en terapia
PE20191245A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
PE20130184A1 (es) Compuesto heterociclico
PE20141308A1 (es) Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a
PE20110419A1 (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk
PE20161073A1 (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
PE20141855A1 (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
PE20110411A1 (es) Imidazopiridazinacarbonitrilos como inhibidores de quinasa
PE20150153A1 (es) 7H-PIRROLO[2,3-d]PIRIMIDINAS 4-(AMINO-SUBSTITUIDAS) NOVEDOSAS COMO INHIBIDORES DE LRRK2
PE20171177A1 (es) Compuestos aminopirimidinilo inhibidores de jak
PE20151249A1 (es) Derivados de pirazolopirimidina como inhibidores de jak quinasas
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
PE20161292A1 (es) Compuestos de nicotinamida sustituida con heteroarilo
PE20180024A1 (es) Triazolopirazinonas como inhibidores de pde1
PE20160664A1 (es) Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina
PE20160875A1 (es) Compuestos de biaril-amida como inhibidores de cinasa
MX2016001011A (es) Derivados de quinazolin-4-ona sustituida.
PE20141203A1 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
PE20121352A1 (es) Derivados de heteroarilo que contienen n como inhibidores de cinasa jak3
PE20200724A1 (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
PE20130279A1 (es) Compuestos heteroarilo nitrogenados
PE20131343A1 (es) Derivados de acido benzoico

Legal Events

Date Code Title Description
FG Grant, registration